Aberdeen Group plc Purchases 77,511 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Aberdeen Group plc increased its stake in Structure Therapeutics by 45.2%, acquiring an additional 77,511 shares, bringing its total holdings to 248,899 shares valued at approximately $4.3 million.
• Institutional investors collectively own 91.78% of Structure Therapeutics, with notable increases from firms such as Deep Track Capital LP, which raised its position by 129.4% in the fourth quarter.
• Recent analyst reports noted a downward adjustment in price targets for Structure Therapeutics, with JMP Securities lowering it from $89.00 to $87.00 while still maintaining a "market outperform" rating.

Aberdeen Group plc grew its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 45.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 248,899 shares of the company's stock after acquiring an additional 77,511 shares during the quarter. Aberdeen Group plc owned about 0.43% of Structure Therapeutics worth $4,308,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Invesco Ltd. boosted its holdings in shares of Structure Therapeutics by 6.1% during the 1st quarter. Invesco Ltd. now owns 394,386 shares of the company's stock valued at $6,827,000 after acquiring an additional 22,619 shares during the last quarter. National Bank of Canada FI boosted its holdings in shares of Structure Therapeutics by 1,448.2% during the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after acquiring an additional 2,766 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Structure Therapeutics by 310.7% during the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock valued at $74,000 after acquiring an additional 3,213 shares during the last quarter. Readystate Asset Management LP boosted its holdings in shares of Structure Therapeutics by 129.9% during the 1st quarter. Readystate Asset Management LP now owns 481,241 shares of the company's stock valued at $8,330,000 after acquiring an additional 271,899 shares during the last quarter. Finally, Banque Pictet & Cie SA boosted its holdings in shares of Structure Therapeutics by 10.2% during the 1st quarter. Banque Pictet & Cie SA now owns 81,766 shares of the company's stock valued at $1,415,000 after acquiring an additional 7,589 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Analysts Set New Price Targets

GPCR has been the topic of a number of research reports. HC Wainwright dropped their price objective on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. JMP Securities dropped their price objective on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Citigroup initiated coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective on the stock. Finally, Guggenheim dropped their price objective on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, According to MarketBeat, Structure Therapeutics has a consensus rating of "Buy" and a consensus price target of $75.71.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock traded up $0.25 on Tuesday, hitting $18.82. 424,017 shares of the company traded hands, compared to its average volume of 900,051. The stock has a market capitalization of $1.08 billion, a P/E ratio of -17.92 and a beta of -1.89. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $13.22 and a 52 week high of $45.37. The business has a 50-day simple moving average of $19.16 and a 200 day simple moving average of $20.95.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). Research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.